150
Participants
Start Date
April 1, 2016
Primary Completion Date
September 14, 2017
Study Completion Date
September 29, 2017
E/C/F/TAF
150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
F/R/TAF
200/25/25 mg FDC tablet administered orally once daily
LDV/SOF
90/400 mg FDC tablet administered orally once daily
University of Miami, Miami
University of Alabama at Birmingham, Birmingham
Spectrum Medical Group, Phoenix
Mills Clinical Research, Los Angeles
Peter J Ruane MD Inc, Los Angeles
University of California Davis, Sacramento
University of California San Diego, San Diego
Kaiser Permanente, San Francisco
The George Washington University Medical Center, Washington D.C.
Whitman-Walker Health, Washington D.C.
Community AIDS Network, Clearwater
Gary Richmond, MD, PA, Inc., Fort Lauderdale
Therafirst Medical Center, Fort Lauderdale
Midway Immunology & Research Center, LLC, Ft. Pierce
AIDS Healthcare Foundation, Miami
AIDS Healthcare Foundation, Miami Beach
Orlando Immunology Center, Orlando
St. Josephs Comprehensive Research Institute, Tampa
Triple O Research Institute PA, West Palm Beach
Rowan Tree Medical PA, Wilton Manors
AIDS Research Consortium of Atlanta, Atlanta
Emory University, Atlanta
Chatham County Health Department, Savannah
The CORE Foundation, Chicago
Be Well Medical Center, Berkley
Kansas City Free Health Clinic, Kansas City
Saint Michael's Medical Center, Newark
Weill Cornell Medical College, New York
University of North Carolina at Chapel Hill, Chapel Hill
Duke University, Durham
East Carolina University, Greenville
Lehigh Valley Health Network, Network Office of Research and Innovation, Allentown
Philadelphia FIGHT, Philadelphia
University of Pennsylvania, Philadelphia
Central Texas Clinical Research, Austin
UT Southwestern Medical Center, Dallas
Gordon E. Crofoot MD PA, Houston
Therapeutics Concepts, PA, Houston
Clinical Alliance for Research & Education, Annandale
Peter Shalit MD, Seattle
Southern Cal, Spokane
Community Health Care, Tacoma
Clinical Research Puerto Rico Inc, San Juan
Lead Sponsor
Gilead Sciences
INDUSTRY